Antibiotic use—particularly regimens that last for two months or more—was linked to an increased risk of CVD in a recent study of nearly 36,500 older women.

Five milligrams of rivaroxaban per day added to a patient’s standard therapy for heart failure (HF) and coronary artery disease (CAD) could reduce that patient’s risk of future thromboembolic events, researchers reported in JAMA Cardiology April 24.

Guerbet, a medical imaging company out of Villepinte, France, this week announced it received CE mark approval for its SeQure and DraKon devices, two microcatheters that facilitate the intra-arterial delivery of therapies and embolic materials to peripheral vessels.

Pennsylvania-based health company Orchestra BioMed has obtained FDA breakthrough device designation for its Virtue sirolimus-eluting balloon (SEB), according to a statement issued April 24.